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Abstract 
 
Joint inflammation is present in a subpopulation of knee osteoarthritic (KOA) patients. Pro-
inflammatory cytokines are known to sensitize the peripheral and central pain pathways. This can be 
mechanistically assessed by pressure pain thresholds and temporal summation of pain (TSP).  Non-
steroidal anti-inflammatory drugs (NSAIDs) combined with paracetamol are recommended as OA 
treatment. The current study hypothesized that evidence of central sensitization would predict poor 
responses to peripherally directed therapies in KOA and therefore aimed to investigate the value of 
mechanistic pain profiling for predicting pain outcome of treatment with NSAIDs plus paracetamol.  
One-hundred-and-thirty-two patients received Ibuprofen 1200 mg/daily, paracetamol 3g/daily, and 
pantoprazole 20 mg/daily for 3-weeks. Prior to administration, cuff pain detection, tolerance threshold 
and TSP were assessed. Worst pain within the last 24-hours and pain during activity (visual analog 
scales) were assessed before and after treatment.  
Facilitated TSP was found at baseline in the non-responders to the 3-weeks  treatment as compared 
with responders for both the 30% and 50% pain alleviation criteria (P<0.02). Linear regression models 
identified facilitated TSP (P<0.01) and low clinical p in scores (P<0.001) as independent factors for 
prediction of poor pain alleviation by the treatment.    
In conclusion, this study found that mechanistic pain profiling can predict pain alleviation of NSAIDs 
and paracetamol. Facilitated TSP and low clinical pain scores prior to treatment are independent 
predictors of poor pain alleviation following NSAIDs and paracetamol. This study adds to the growing 
evidence that a subgroup of KOA patients with manifested central sensitization may require special 
management attention.   
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Introduction 
 
Musculoskeletal pain is an increasingly large clinial problem and knee osteoarthritis (OA) is the most 
common joint condition[55]. The mechanisms underlying pain in knee OA are largely unknown[2], but 
recent studies indicate that inflammation is present in a subpopulation of knee OA patients[53] and that
increased inflammation is associated with increased pain severity[17,18].  
Pro-inflammatory cytokines are known to sensitize th  peripheral nerve endings leading to 
hyperalgesia[50], which can be assessed as lowered pressure pain thresholds (PPTs). A prolonged 
intense painful input from the periphery may sensitize he dorsal horn neurons leading to an increased 
central gain of pain. This phenomenon can be assessed as facilitated temporal summation of pain 
(TSP)[22]. Widespread hyperalgesia can in part be explained by impaired descending pain control 
which is considered the net effect of pain inhibitory and facilitatory pathways[6,59]. Mechanistic pain 
profiling using quantitative sensory testing (QST) has demonstrated local and widespread pressure 
hyperalgesia and facilitated TSP in patients with severe knee OA compared with pain-free subjects[4]. 
Further, mechanistic pain profiling of knee OA patien s has found preoperative TSP and PPTs to be 
predictive of the development of chronic postoperative pain following total joint replacement 
[27,39,40,42,58]. These parameters are normalized aft r a successful TKA recovery leading to a pain-
free outcome [24,31] and this highlights the significance of such mechanisms as targets for pain 
management.  
The combination of non-steroidal anti-inflammatory d ugs (NSAIDs) and paracetamol is considered 
the first line of treatment for painful knee OA [26, 8]. Analgesic effects have been widely documented 
even though the mechanisms of action are not completely understood[21]. Further, it cannot be 
predicted which patients would benefit most from the treatment. NSAIDs may be potentially 
harmful[34]. Hence patients who do not benefit sufficiently from the treatment should not be exposed 
to this risk. Both NSAIDs and paracetamol inhibit the synthesis of prostaglandins modulated through 
cyclooxygenase (COX). In the rat, non-selective NSAIDs and paracetamol enhance the activity of the 
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cannabinoid system[1], and studies suggest that the analgesic effect of NSAIDs and selective COX-2 
inhibitors is dependent on an intact serotonin system[21]. Further, COX-2 inhibitors modulate 
widespread hyperalgesia[34,46] suggesting that NSAID treatment may also modulate central pain 
pathways and that mechanistic pain profiling could identify responders to NSAID treatment. Finally, 
facilitated TSP prior to treatment has been found to be associated with pain alleviation in responders to 
selective COX-2 inhibitors in knee OA[3].   
The effect size of the combination of NSAIDs and paracetamol is larger than either NSAIDs or 
paracetamol alone[38]. In this context, the combinatio  of  1.2 gram Ibuprofen and 3 gram paracetamol 
per day has been found superior to paracetamol alone in osteoarthritic pain[14]. Long-term use of 
NSAIDS may pose serious health risks [34] and hence tools for predicting the possible benefits are 
warranted. A recent study found that a reduction in the brain blood oxygen level–dependent signal 
activation of the sensory cortex and supramarginal gyrus in OA patients was associated with poor pain 
alleviation following treatment with paracetamol[60]. This indicates that measures of central 
sensitization could add prognostic information in trea ment of OA. Therefore, the current study 
hypothesized that centrally sensitized OA patients would receive poor or limited analgesic effects of 
NSAIDs plus paracetamol and aimed to use mechanistic pain profiling as a tool to predict the efficacy 
of a 3-week NSAIDs plus paracetamol treatment in patients with painful knee OA. 
Methods  
Protocol 
A consecutive cohort of knee OA patients were recruited between January 2016 and February 2018. 
Data were collected at the Orthopedic Outpatient Clinic at Aalborg University Hospital, Aalborg, 
Denmark. The study was approved by The North Denmark Region Committee on Health Research 
Ethics (N-20140077) and registered at ClinicalTrials.gov (NCT02967744). Written informed consent 
was obtained before patient inclusion. Clinical OA was defined following the American College of 
Rheumatology criteria[56]. The peak pain intensity within the last 24 hours and the pain during activity 
(visual analog scale, VAS), the Knee Injury and Osteoarthritis Score (KOOS) and quantitative sensory 
testing (QST) recordings (pressure pain detection threshold (cPDT), and pain tolerance threshold 
(cPTT) and TSP) were collected before treatment. The exclusion criteria included the presence of other 
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pain problems (e.g. hip OA), sensory dysfunction (e.g. fibromyalgia, neuropathic pain), or mental 
impairment.  
Treatment  
Patients were administrated Ibuprofen 400 mg (three tim s per day), Paracetamol 1g (three times per 
day) and Pantoprazole 20 mg (once per day) for 3-weeks. Patients were instructed to report all adverse 
and severe adverse events. 
Clinical assessment of pain and function  
KOOS, a 42-item self-administered questionnaire[49] assessing five separate dimensions: pain, 
symptoms, activities of daily living (ADL), sport and recreation function (Sport/Rec), and knee-related 
quality of life (QOL), was administrated before and after treatment. A percentage score from 0% to 
100% was calculated for each dimension; 100% represnting the best possible score. 
The worst pain within the last 24 hours and the pain during activity were assessed using a VAS before 
and after treatment. The VAS was anchored at 0 cm: no pain and 10 cm: worst pain imaginable.  These 
assessments have been consistently used in similar studies[27,39,41–43]. 
Quantitative sensory testing 
Deep-tissue pain sensitivity was evaluated by cuff pressure stimuli using a computer-controlled cuff 
algometer (Cortex Technology and Aalborg University, Denmark) including a 13-cm wide tourniquet 
cuff (VBM, Sulz, Germany) and an electronic VAS (Aalborg University, Denmark) for recording of 
the pain intensity. The cuff was placed at the level of the head of the gastrocnemius muscle of the leg 
most affected by OA. The electronic continuous VAS (sliding resistor) was 10 cm long and sampled at 
10 Hz; 0 cm indicated “no pain” and 10 cm indicated “maximum pain”. 
 
Cuff pain detection and tolerance threshold 
The pressure (in kPa) was increased by 1 kPa/s and the patient was instructed to rate the pain intensiy 
continuously on the electronic VAS until the tolerance level was reached. The patients were instructed 
to press a stop button at this point of time. The pressure pain detection threshold (cPDT) was defined as 
the pressure at which the VAS score exceeded 1 cm[23]. The pain tolerance threshold (cPTT) was 
defined when the patient pressed the stop button. cPDT and cPTT were assessed bilaterally.  
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Temporal summation of pain 
Ten short-lasting stimuli (1 s each) at the level of the cPTT were given with a 1 s break between 
stimuli. The participants were instructed to continuously rate the pain intensity of the sequential stmuli 
using the electronic VAS and not to return to zero during the breaks. For each cuff stimulus, a VAS 
score was extracted and TSP was defined as the difference between the tenth and the first VAS 
score[39]. 
Statistical analysis 
The data are presented as means and standard error of the mean (SEM) if not otherwise stated. Paired 
sample t-tests were used to compare VAS and KOOS data before and after treatment. The patients were 
divided into responders and non-responders based on a 30% or a 50% pain alleviation from the 
treatment using the VAS scale. Pre-treatment parameters (VAS, cPDT, cPTT and TSP) were compared 
between the two groups (responders and non-responders) using independent sample t-tests. Finally, 
linear regression models were used to define independent factors and to predict the analgesic effect of 
the treatment using the mechanistic pain profiles and clinical pain intensity (VAS) prior to treatment. 
The statistical analyses were performed using SPSS (version 23, IBM Corporation, New York, USA). 
P-values < 0.05 were considered significant. 
Results 
Clinical assessments of pain, function and quality of life 
One-hundred-and-sixty-two patients were recruited an  132 patients had complete follow-up data after 
treatment and were included in the current analysis. Significantly decreased pain during activity and 
worst pain during the last 24 hours (P<0.001), increased KOOS pain (P<0.001), KOOS symptoms 
(P<0.001) and KOOS ADL (P<0.001) were found at follow-up compared with before treatment values; 
see table 1.  
Clinical and mechanistic pain profiles based on a 30% pain alleviation 
Fifty-two (39%) of 132 patients obtained a 30% pain relief based on the worst pain within the last 24 
hours. Further, this group showed significantly increased KOOS symptoms (P=0.028), KOOS ADL 
(P=0.007), a trend towards significantly increased KOOS QOL (P=0.056) and a trend towards 
significantly increased KOOS Pain (P=0.071) before treatment compared with the group which did not 
obtain 30% pain relief. These figures are based on w rst pain within the last 24 hours. Sixty (45%) of 
AC
CE
TE
D
Copyright  8 8 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.            201
6 
 
132 patients obtained a 30% pain relief based on pain during physical activity. This group had 
significantly increased KOOS pain (P<0.001), KOOS symptoms (P=0.005), KOOS ADL (P<0.001) 
and increased KOOS QOL (P=0.010) before treatment compared with the group which did not obtain a 
30% pain relief.  In addition, based on the 30% pain alleviation criterion of pain during activity and 
worst pain during the last 24 hours, non-responders compared with responders showed facilitated TSP 
prior to treatment (P<0.020, figure 1) but no differences in cPDT or cPTT. 
Clinical and mechanistic pain profiles based on a 50% pain alleviation 
Thirty-three (25%) of 132 subjects obtained a 50% pain relief based on the worst pain within the last 24 
hours. This group was not significantly different wi h regard to any clinical assessments of pain, 
function or quality of life (P>0.2). Based on the 50% pain relief using the pain during physical activity, 
42 patients (32%) had significantly increased KOOS pain (P=0.004), KOOS symptoms (P=0.018), 
KOOS ADL (P=0.004) and increased KOOS QOL (P=0.007) before treatment compared with the 
group which did not obtain a 50% pain relief. 
Based on the 50% pain alleviation criterion of pain during activity and worst pain during the last 24 
hours, non-responders compared with responders showed facilitated TSP prior to treatment (P<0.023, 
figure 1) but no differences in cPDT or cPTT. 
Prediction models of pain alleviation following treatment 
Several linear regression models were established to investigate the predictive value using the 
mechanistic pain measures and clinical pain prior to t eatment. Model 1, consists of all the mechanistic 
pain measures and pain prior to treatment with predictive values (R2) of 24.6% for worst pain within 
the last 24 hours and 27.8% for pain during activity and identified pain intensity (P<0.001) and TSP 
(P<0.008) prior to treatment as significant factors; table 2. Model 2, constricted to significant factors 
only (using backwards selection), showed with predictive values (R2) of 24.0% for worst pain within 
the last 24 hours and 26.9% for pain during activity with pain intensity (P<0.001) and TSP (P<0.009) 
prior to treatment as significant factors (table 2). The predictive values of model 2 were not 
significantly different from model 1 (P>0.5), indicating that facilitated TSP and lower pain intensity 
prior to treatment are the most important features in these models and predict a poor or limited 
analgesic effect to NSAID plus paracetamol. In addition, linear regression models define independent 
factors illustrating that pain prior to treatment ad TSP are independent factors for the prediction of the 
analgesic effect of NSAIDs plus paracetamol.  
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Discussion  
 
The current study is the first large sized mechanistic pain profiling trial to predict an analgesic response 
following a 3-week NSAIDs and paracetamol combination in patients with painful knee osteoarthritis. 
The study found that approx. 40% of the patients obained a 30% analgesic effect and that approx. 25% 
of the subjects obtained a 50% analgesic effect following the 3-weeks of NSAIDs plus paracetamol. In 
addition, non-responders to the 30% and 50% cutoff criteria were characterized by facilitated TSP 
before treatment compared with responders. Finally, the linear regression models identified facilitated 
TSP and lower clinical pain intensity prior to treatment as independent factors associated with the poor 
or limited analgesic effect of NSAIDs plus paracetamol.  
Analgesic effect of NSAIDs plus paracetamol for oste arthritis 
NSAIDs and/or paracetamol are considered the first line of medications for treating osteoarthritic 
pain[26,28]. On average, pain alleviation from analgesics in OA is approx. 20-25% (except the anti-
NGF compounds,  which show stronger effects)[52]. It is currently debated if and how responders to 
treatment can be classified. The Osteoarthritis Research Society International (OARSI) Standing 
Committee for Clinical Trials Response Criteria Initiat ve and the Outcome Measures in Rheumatology 
(OMERACT) Committee have defined a responder as either 1) an improvement in pain and function by 
at least 50% or 2) an improvement by at least 20% in two of the following three categories: pain, 
physical function or global assessment of the patient [44]. The current study reported a 28.6% pain 
reduction when assessing the worst pain within the last 24 hours, 31.5% when assessing the pain during 
activity and a 14.8% pain reduction when assessing the KOOS pain subscale. This illustrates that the 
method used for pain assessment would greatly affect th  OMERACT-OARSI responder criteria.  
Studies have found that the majority of the pain improvement occurs within the first weeks of 
treatment[12,45]. This further supports the short administration period in the current study compared 
with previous long-term studies showing less convincing long-term effects[9]. 
NSAIDs plus paracetamol and mechanistic pain profiling 
The mechanisms underlying pain in OA are largely unknown complicating the treatment of the pain. 
Recent evidence suggests that inflammatory markers ar  associated with osteoarthritic pain[17,51,53] 
and that inflammatory markers are known to sensitize the peripheral nerve endings resulting in 
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hyperalgesia[50]. Both localized and widespread hyperalgesia are  found in knee OA patients with high 
clinical pain intensities [7,16]. NSAIDs inhibit the synthesis of prostaglandins[21], which in turn will
blunt the activation of leukocytes thereby minimizing the inflammatory cascade. In theory, this should 
dampen hyperalgesia. Pre-clinical data suggest that loc lly upregulated prostaglandins will induce 
peripheral hyperalgesia and that upregulated prostaglandins in the central nervous system will induce 
widespread hyperalgesia[46,57]. Interestingly, spinal administration of COX-2 inhibitors in an animal 
inflammatory model reduces prostaglandin subtype E2 and reduces peripheral mechanical 
hyperalgesia[46,57] indicating that COX-2 acts on ce tral pain mechanisms as recently shown in knee 
OA patients[3]. Both COX-2 inhibitors[47] and non-selective COX inhibitors[8,10,25] are found in the 
cerebrospinal fluid after oral administration in humans. This should modulate locally and widespread 
hyperalgesia and lead to an analgesic effect. This theory is in contrast to the current study, which found 
that facilitated TSP (as a measure of central gain of pain) was associated with less pain alleviation 
following 3 weeks of NSAIDs plus paracetamol.  
A previous study has found that approx. 50% of patients experience an additional pain relieving effect 
when switching from NSAIDs to etoricoxib (a selective COX-2 inhibitor)[33] indicating an additional 
analgesic effect of administering etoricoxib compared with traditional NSAIDs (COX-1 and COX-2). 
However, this needs validation in large clinical cohorts.  
The predictive value of mechanistic pain profiling  the treatment of osteoarthritic pain 
Recent reviews have concluded that there is a neuropathic component in a subpopulation of OA 
patients[6,13]. The PainDetect questionnaire aims to identify a positive, unclear and negative 
neuropathic pain component in chronic pain patients[20], and studies have identified 5 - 30%[32,35,37] 
of OA patients with a positive neuropathic pain comp nent. Furthermore, OA patients with a positive 
neuropathic pain component have been found to report higher pain intensities and widespread pressure 
hyperalgesia compared with an unclear or negative neuropathic pain component[35]. Finally, a recent 
study found that OA patients with a positive neuropathic pain component display preoperatively 
widespread hyperalgesia, facilitated TSP and report higher pain intensities six months after total knee 
arthroplasty (TKA) compared with patients with an unclear or negative neuropathic pain 
component[32].   
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The pain sensitivity has been suggested to increase with increasing pain duration and pain intensity in 
knee OA[7]. Recent phenotyping of knee OA patients ba ed on radiological OA severity and pain 
intensity has revealed that patients characterized by high pain intensities but low radiological OA are 
highly pain sensitive[5,19] and respond poorly to TKA[42,48]. Several recent studies have revealed 
that preoperative pressure pain thresholds[40], TSP[39,42], or CPM[54] are predictive of poor outcome 
after TKA indicating that highly centrally pain sensitive knee OA patients do not respond well to TKA. 
Recently, O’Leary et al.[36] found that facilitated TSP and low PPTs were predictive of poor outcome 
for knee OA patients following physiotherapy. The current study further indicates that knee OA 
patients with facilitated TSP do not respond optimally to standard anti-inflammatory treatment, which 
is in line with a previous study regarding topical NSAIDs in knee OA[16].  
Conclusively, accumulating evidence suggests that knee OA patients defined as “centrally sensitized” 
might not respond to the guidelines by OARSI[61] and hence the new pain descriptor “nociplastic” 
may apply to such conditions[30].  
Future research should aim to link mechanistic painrofiling to pain alleviation using these drugs in 
OA patients who are characterized as centrally painsensitive to enhance our understanding of the 
treatment options.  
Limitations 
It could be argued that this exploratory study is limited by the lack of a placebo group. The aim of the 
study was not to compare with placebo but to investigate if the outcome after a well-known therapy 
could be predicted. Several studies have shown that the analgesic effects of NSAIDs plus paracetamol 
are superior to placebo[11,12,15,29,45]. The aim of the study was to investigate the value of 
mechanistic pain profiling and its predictive value after NSAIDs and paracetamol treatment as 
mechanistic pain profiling has previously been shown to identify poor responders to other standardized 
OA treatments [36,39,40,42,54].  Predicting poor NSAID treatment outcome is valuable as patients not 
responding adequately should not be treated with NSAIDs due the possible unwanted side effects.  
Conclusion  
The mechanistic pain profiling identified non-responders to standard pharmacological treatment. This 
study adds to the growing evidence that a subgroup of OA patients who are specifically centrally pain 
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sensitive (facilitated TSP) may require special management attention. Avoiding NSAID treatment in 
patients not benefitting is important to protect those patients from unwanted side effects.  
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Figure legends  
Figure 1: Temporal summation of pain in knee osteoar hritic patients grouped into responders and non-
responders based on a pain alleviation of at least 30% or 50% following 3 weeks of NSAIDs and 
paracetamol for the worst pain within the last 24 hours (worst pain) or pain during activity (Activity). * 
indicate significant differences (P<0.05) between rsponders and non-responders. 
 
  
AC
CE
PT
ED
Copyright  8 8 by the International Association for the Study of Pain. Unauthorized reproduction of this article is prohibited.            201
17 
 
Table 1: Mean and standard error of the mean (SEM) from 132 knee osteoarthritis patients before and 
after treatment.  
 Before treatment 
Mean (SEM) 
After treatment 
Mean (SEM) 
 
Percentage 
change 
P-value 
Age (years) 60.01 (0.81)    
BMI [kg/m2] 29.15 (0.46)    
Gender (percentage 
female) 
52.6%    
Pain intensity [cm] 
- worst pain within 
the last 24 hours 
- During activity 
 
 
 
6.88 (0.20) 
6.38 (0.23) 
 
 
4.91 (0.26) 
4.37 (0.29) 
 
 
28.6% 
31.5% 
 
 
<0.001 
<0.001 
KOOS subscales     
- Pain 52.45 (1.50) 60.20 (1.63) 14.8% <0.001 
- Symptoms 59.18 (1.71) 64.15 (1.88) 8.4% <0.001 
- ADL 58.63 (1.71) 65.31 (1.84) 11.4% <0.001 
- QoL 36.54 (1.40) 39.36 (2.78) 7.7% 0.242 
BMI: Body mass index, KOOS: Knee Injury and Osteoarthritis Score, ADL: Function in daily living, 
QoL: Quality of life. 
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Table 2: Linear regression models using mechanistic pain profiling and pain intensity prior to 3 weeks 
of non-steroidal anti-inflammatory drugs and paracet mol treatment of patients with knee osteoarthritis.  
  Worst pain within the last 24 
hours 
Pain during activity 
Model Variable   
Standardized 
     coefficient 
P-value  R2 Standardized 
coefficient 
P-value R2 
1    0.246   0.278 
 Pain intensity prior 
to treatment 
0.474 <0.001  0.471 <0.001  
 cPDT (ipsilateral) -0.026 0.861  0.084 0.574  
 cPTT (ipsilateral) -0.064 0.688  -0.024 0.880  
 cPDT 
(contralateral) 
-0.028 0.849  -0.067 0.642  
 cPTT (contralateral) 0.130 0.387  0.096 0.515  
 TSP 0.220 0.008  -0.264 0.002  
2    0.240   0.269 
 Pain intensity prior 
to treatment 
0.472 <0.001  0.472 <0.001  
 TSP -0.217 0.009  -0.264 0.001  
 
Model 1 included pain intensity, cuff pain detection (cPDT) and tolerance thresholds (cPTT) assessed 
bilaterally and temporal summation of pain (TSP) asses ed prior to treatment. Model 2 included 
significant factors from model 1 (using backwards selection). R2 indicate the predictive value of each 
model.  AC
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